Omeros Corporation (OMER)

Market Cap	349.44M
Revenue (ttm)	n/a
Net Income (ttm)	-134.53M
Shares Out	57.95M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,013
Open	6.00
Previous Close	6.03
Day's Range	5.89 - 6.20
52-Week Range	1.66 - 7.51
Beta	1.48
Analysts	Buy
Price Target	9.00 (+49.25%)
Earnings Date	Nov 13, 2024

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 198
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Forecast

According to 3 analysts, the average rating for OMER stock is "Buy." The 12-month stock price forecast is $9.0, which is an increase of 49.25% from the latest price.

Price Target

$9.0

(49.25% upside)

Analyst Consensus: Buy